SLC5A2 and diabetes mellitus: Inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) reduces albuminuria and slows the rate of progression in proteinuric kidney diseases, particularly in diabetes, and newer anti-hyperglycemic agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have reno-protective effects [8, 9].